Key Highlights

  • Niki BioSolutions, Inc. (NASDAQ:NIKI) rose 9.84% to about USD 2.01 in early trading on Monday, October 26, 2026, after a company release at 9:15 a.m. ET on a New York State approval.
  • The approval, dated Friday, October 23, 2026, expands the specimen types for the APOE Genotyping test to dried blood spots, plasma and urine, from blood, buccal swab, saliva and tissue.
  • The test was first approved in August 2025 and identifies genetic variants linked to Alzheimer's disease risk and other conditions, and plasma can also serve the company's microRNA brain health assay.
  • The company, formerly Aptorum Group Limited, describes itself as clinical-stage, and the release gives no revenue, volume or price guidance for the expanded test.

An Approval Announced Ahead of the Open

Niki BioSolutions, Inc. (NASDAQ:NIKI), a life sciences company that develops genomic and biomarker tests, rose 9.84% to about USD 2.01 in early trading on Monday, October 26, 2026. The move followed a company release at 9:15 a.m. ET that day. Its wholly owned subsidiary, DiamiR Biosciences Corp., received a Clinical Laboratory Evaluation Program test approval from the New York State Department of Health on Friday, October 23, 2026. The approval adds dried blood spots on FTA cards, plasma and urine to the specimen types for the APOE Genotyping test, which was first approved in August 2025 for blood, buccal swab, saliva and tissue. The company operates a laboratory with federal clinical certification and accreditation from the College of American Pathologists.

Why Specimen Types Matter for Testing

APOE genotyping looks for variants of a gene associated with Alzheimer's disease risk. For Niki BioSolutions, Inc. (NASDAQ:NIKI), the practical value of the approval lies in logistics. The release says dried blood spots and similar samples could support at-home or point-of-care collection and shipping at ambient temperature, without a blood draw by a phlebotomist or cold-chain handling, meaning refrigerated transport. Plasma can also serve the company's microRNA-based brain health assay, so both tests could run from one blood draw. In New York, laboratory tests offered to residents require state approval, so each added specimen type widens the set of samples the laboratory may accept and may lower the cost of collection.

Risks and What to Watch

The release does not quantify revenue, test volume or pricing, so the commercial effect of the approval remains unmeasured for Niki BioSolutions, Inc. (NASDAQ:NIKI). A state approval permits testing for New York samples but does not itself create demand, reimbursement or physician adoption. The company describes itself as clinical-stage, and the share price near USD 2.01 suggests a small capitalisation, which raises liquidity and dilution risk. The company was previously named Aptorum Group Limited, so investors should read filings under both names. Investors should watch for the next quarterly results, any financing, adoption data for the expanded specimen types and the Fed decision on Wednesday, October 28, 2026.

Where Things Stand

The answer is that Niki BioSolutions, Inc. (NASDAQ:NIKI) rose 9.84% to about USD 2.01 in early trading on Monday, October 26, 2026 because a New York State approval widened the specimens its APOE Genotyping test may use. The next catalysts are any commercial update on the test, the next quarterly results and the Fed decision on Wednesday, October 28, 2026. Small healthcare listings can reverse quickly, regulatory approvals do not guarantee sales, and this is not investment advice.